Comparison of cost-effectiveness studies on durvalumab.
收藏NIAID Data Ecosystem2026-03-13 收录
数据链接：
官方服务：
资源简介：
Comparison of cost-effectiveness studies on durvalumab.
应用场景：
创建时间：
2022-06-24
相关数据集
Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and Payer’s Perspective) 1/ .
Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and Payer’s Perspective) 1/.
NIAID Data Ecosystem30
Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants
Aims: Non-valvular atrial fibrillation (NVAF) prevalence increases with age. Hence, evaluating the economic burden among older-aged patients is vital. This study aimed to compare healthcare res
Taylor & Francis Group2024-02-28 更新10
The heterogeneity in the cost per case avoided with coxibs stratified by the number of major risk factors and exposure characteristics (with the cost per case avoided estimated for each individual prescription).
#Each NSAID prescription was classified according to first-ever use, long gap (previous prescription at least 6 mo before), and short gap (previous prescription within the last 6 mo). The medication p
Figshare2015-12-02 更新10
Table 1_Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.docx
IntroductionRemdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe
NIAID Data Ecosystem10
Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.
Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.
Figshare2018-07-18 更新10
